April 16 (Reuters) - An experimental once-daily combination
hepatitis C treatment being developed by AbbVie Inc
demonstrated very high cure rates across a wide range of disease
genotypes, according to data presented on Saturday, likely
giving the company a more competitive product if approved.
Read more
No comments:
Post a Comment